Advertisement

DHR

Danaher Corporation

Healthcare · USD

Set alert

Price alert · DHR

All alert types
232.23 USD -4.75 -2.00%
As of Oct 30, 2026 Extended hours 233.00 +0.33%
Bid
232.25 × 200
Ask
232.42 × 300
230.46 Day range 238.38
161.91 52-week range 242.05
YTD
+1.45%
1 year
+7.99%
Open
238.46
Prev close
236.98
Mkt cap
163.25B
Vol
3.75M
Avg vol
4.03M
EPS
6.04
P/E
38.45
Div yield
0.68%
More statistics
Low
230.46
High
238.38
Forward P/E
24.93
Beta
0.80
Short ratio
1.76
Inst. own
83.68%
Dividend
1.60
Ex-div date
Sep 29, 2026
Earnings
Jan 27, 2027
50-d avg
218.53
200-d avg
201.14
1y target
259.90

5D chart

Chart tools
Interval
DHR five-day price chart229.3231.6233.9236.2238.5Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
163.30B
Enterprise value
188.83B
Trailing P/E
38.46
Forward P/E
24.93
PEG ratio
1.35
Price / sales
6.38
Price / book
3.05
EPS (TTM)
6.04
Beta
0.80
Dividend yield
0.68%
Payout ratio
25.17%
Profit margin
16.91%
Revenue (TTM)
25.61B
Revenue growth
8.30%
Free cash flow
4.75B
Total cash
5.68B
Total debt
27.78B
Return on equity
8.19%
Shares outstanding
702.99M
Short % of float
1.30%
50-day average
218.53
200-day average
201.14

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 259.90 +11.9% upside
Target (low)
220.00
Target (mean)
259.90
Target (high)
310.00
Ratings (0m) 24 20 buy · 4 hold · 0 sell
  • Strong buy3
  • Buy17
  • Hold4
  • Sell0
  • Strong sell0

Next earnings

Jan 27, 2027

Expected Jan 27, 2027. Consensus EPS estimate 2.48.

Earnings history

Financials — quick view

All financials
DHR Revenue — quarterly 6.55B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
DHR Net income — quarterly 1.24B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
DHR EPS — quarterly 1.75
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

DHR recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 27, 2027Dec 25, 20262.49———
Oct 21, 2026Sep 25, 20261.922.11+0.19+9.90%
Jul 21, 2026Jun 26, 20261.851.94+0.09+4.86%
Apr 21, 2026Mar 27, 20261.942.06+0.12+6.19%
Jan 28, 2026Dec 31, 20252.162.23+0.07+3.24%
Oct 21, 2025Sep 26, 20251.721.89+0.17+9.88%

Upgrades / downgrades

DHR analyst upgrades and downgrades
DateFirmActionFromTo
Oct 22, 2026CitigroupmainBuyBuy
Oct 22, 2026BarclaysmainOverweightOverweight
Oct 22, 2026JP MorganmainOverweightOverweight
Oct 22, 2026TD CowenmainBuyBuy
Oct 22, 2026StifelmainBuyBuy
Oct 22, 2026BairdmainOutperformOutperform

About Danaher Corporation

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
danaher.com

News

Your note

Sign in to keep a note on DHR — it syncs with the Stock Master app.

Insider holders

DHR insider holders
InsiderRelationLatest transactionDateShares held
BLAIR RAINER MChief Executive OfficerSaleAug 20, 20260
FILLER LINDADirectorConversion of Exercise of derivative securityJul 14, 202648,419
GUTIERREZ-RAMOS JOSE-CARLOSOfficerStock Award(Grant)Aug 3, 202632,495
MCGREW MATTHEWOfficerStock Award(Grant)Feb 26, 202637,063
RALES MITCHELL POfficer and DirectorStock Award(Grant)Aug 3, 202627,509,900
RALES STEVEN MChairman of the BoardStock Award(Grant)Aug 3, 202634,626,700

Institution ownership

DHR institution ownership
Holder% heldSharesValueReported
Blackrock Inc.7.83%55,084,63012.80BJun 29, 2026
Vanguard Capital Management LLC5.88%41,377,0769.61BJun 29, 2026
FMR, LLC4.20%29,540,8956.86BJun 29, 2026
State Street Corporation4.04%28,456,0196.61BJun 29, 2026
Wellington Management Group, LLP2.32%16,316,8343.79BJun 29, 2026
Capital International Investors2.20%15,504,4203.60BJun 29, 2026

Fund ownership

DHR fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.87%20,222,9234.70BJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.32%16,324,1983.79BJun 29, 2026
WASHINGTON MUTUAL INVESTORS FUND1.23%8,680,0622.02BSep 29, 2026
iShares Trust-iShares Core S&P 500 ETF1.19%8,337,0211.94BSep 29, 2026
Fidelity Concord Street Trust-Fidelity 500 Index Fund1.16%8,176,8801.90BAug 30, 2026
SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust1.10%7,741,2061.80BSep 29, 2026
Advertisement